Prevention of Atherosclerosis and Heart Disease in Patients With Systemic Lupus Erythematosis (SLE) [clinicaltrials:NCT00054938]
Prevention of Atherosclerosis and Heart Disease in Patients With Systemic Lupus Erythematosis (SLE) [clinicaltrials:NCT00054938]
Bio2RDF identifier
NCT00054938
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00054938
identifiers.org URI
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
The purpose of this stu ...... cations in people with lupus.
brief title [clinicaltrials_vocabulary:brief-title]
Prevention of Atherosclerosis ...... emic Lupus Erythematosis (SLE)
collaborator [clinicaltrials_vocabulary:collaborator]
completion date [clinicaltrials_vocabulary:completion-date]
2005-12-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
People with SLE are at ...... lowed
for 2 to 4 years.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
enrollment [clinicaltrials_vocabulary:enrollment]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
2003-02-13T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]
is section 801 [clinicaltrials_vocabulary:is-section-801]
keyword [clinicaltrials_vocabulary:keyword]
Accelerated Atherosclerosis
Cholesterol
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2013-12-23T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00054938
official title [clinicaltrials_vocabulary:official-title]
A Randomized Controlled Trial ...... Erythematosus - A Pilot Study
org study id [clinicaltrials_vocabulary:org-study-id]
P60 AR47782 NIAMS-077
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
primary completion date [clinicaltrials_vocabulary:primary-completion-date]
2005-12-01T00:00:00Z
reference [clinicaltrials_vocabulary:reference]
responsible party [clinicaltrials_vocabulary:responsible-party]
secondary id [clinicaltrials_vocabulary:secondary-id]
P60AR047782
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
2003-03-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2013-12-01T00:00:00Z
identifier
clinicaltrials:NCT00054938
title
Prevention of Atherosclerosis ...... emic Lupus Erythematosis (SLE)
@en
type
label
Prevention of Atherosclerosis ...... ) [clinicaltrials:NCT00054938]
@en